Literature DB >> 27387545

Comment on "Regulation of immunity during visceral Leishmania infection" and further discussions about the role of antibodies in infections with Leishmania.

Luiz Gustavo Gardinassi1, Isabel Kinney Ferreira de Miranda Santos2.   

Abstract

Comments on the article "Regulation of immunity during visceral Leishmania infection" published in Parasites & Vectors 2016, 9:118, and further discussions about the role of antibodies in infections with Leishmania.

Entities:  

Keywords:  Antibodies; Fc N-glycosylation; Fc receptors; Immunopathology; Leishmaniasis; Protection

Mesh:

Substances:

Year:  2016        PMID: 27387545      PMCID: PMC4936235          DOI: 10.1186/s13071-016-1669-0

Source DB:  PubMed          Journal:  Parasit Vectors        ISSN: 1756-3305            Impact factor:   3.876


Letter to the editor

Rodrigues and colleagues recently presented in this journal a comprehensive and timely review of the current state of knowledge about immunity to visceralizing species of Leishmania in humans and in animal models [1]. We read with particular interest the topic they devoted to studies that evaluated the role of antibodies, B cells and T follicular helper cells during infections with these intracellular parasites. We strongly agree with the authors’ conclusions about the need to reassess the role of antibodies in these infections, wherein they state that “Rather than considering the role of antibodies solely as pathological or irrelevant, it is perhaps wiser to acknowledge that these molecules may play both protective and non-protective roles during VL”. However, we would like to add further information from studies that provide important evidence and concepts that also support a crucial role of antibodies during infections with Leishmania and that were not considered in their review. As pointed out by Arturo Casadevall, the rationale for dichotomizing types of immunity against extracellular and intracellular pathogens into antibody-mediated and cell-mediated, respectively, is based on concepts that probably originated in the great debate between scientists advocating humoral or cellular immunity at the beginning of the 20th century [2]. However, this concept cannot be applied to every known pathogen, whereby antibodies have been shown to protect against at least some intracellular pathogens such as Trypanosoma cruzi [3, 4], Histoplasma capsulatum [5] and Mycobacterium tuberculosis [6]. Since the majority of early studies on the leishmaniases did not correlate antibody-mediated immunity with protection, many questions about the role of B lymphocytes and antibodies during such infections remained unanswered. However, an initial proof of concept that antibodies can be important for controlling infections with Leishmania comes from the observation that pathogenic Trypanosomatidae express receptors for IgG Fc [7, 8] or proteases for IgG [9], possibly to escape from this effector mechanism. In the early 80’s Anderson and colleagues [10] demonstrated that the protective effect of a monoclonal antibody raised against L. mexicana was dependent on the number of antibody-opsonized parasites inoculated into BALB/c mice [10]. Furthermore, another study showed that monoclonal antibodies raised against L. infantum conferred passive cross-protection against infections with L. amazonensis and L. major in mice [11]. As addressed by Rodrigues and colleagues [1], a study demonstrated that protective immunity against L. major required efficient uptake of IgG-opsonized parasites by dendritic cells through Fc-gamma receptors (FcγR) I and III [12]. More recent work revealed that elimination of L. amazonensis depends in part on the FcγR common-chain and NADPH oxidase-generated superoxide from infected macrophages in vitro [13]. In contrast, a study showed that interactions of mouse IgG1 with FcγRIII is detrimental in infections with L. mexicana, but not interactions with IgG2a/c or IgG3 [14]. Together, these data suggest that the signaling pathways through which phagocytes are activated might be fundamental for the functional profile that these cells will acquire and, therefore, for their effects on polarizing the cell populations that will comprise Leishmania-specific acquired immunity. Notably, mice that lack immunoglobulin-bearing B cells (JhD BALB/c) are considered to be relatively resistant to infection with L. pifanoi, L. amazonensis and L. infantum and passive transfer of B cells, immune serum or purified antibodies to chronically infected JhD BALB/c mice restored susceptibility to infection, respectively [15-17]. In addition, μMT mice (assumed to lack mature B cells) also exhibit a relative resistance when infected with L. major LV39 (BALB/c) [18] or L. donovani (C57BL/6) [19]; however, other work indicates that μ-chain-deficient mice possess functional B-1 cells and can produce non-specific IgG [20, 21]. Indeed, the studies mentioned above did not discriminate between subsets of cells derived from B lymphocytes such as plasma cells, regulatory B cells or marginal zone B cells, which exhibit different functions depending on the context of infection with Leishmania [22-28]. We also highlight that, while mice (BALB/c or C57BL/6) are acutely susceptible to these parasites, they do not develop chronic and progressive disease after infection with L. donovani or L. infantum [29]. Therefore, the role of antibodies in these mouse models of visceral leishmaniasis (VL) and its translation into immunopathological features observed in progressive disease as seen in humans and non-human primates, dogs and hamsters, may warrant reinterpretation. Accordingly, Reis and colleagues [30] observed a strong correlation between levels of IgG1 antibodies specific for soluble antigens from L. infantum promastigotes and an asymptomatic outcome of infection and also a correlation between IgG2 of the same specificity and manifestation of disease in dogs. In another study, Oliveira and colleagues [31] observed that dogs presenting with asymptomatic infections with L. infantum have significantly lower levels of IgG2 antibodies specific for a crude antigen extract from these parasites than symptomatic dogs. Interestingly, these authors also observed that dogs vaccinated with Leishimmune® (Fort Dodge Animal Health) and supposedly protected against disease, present negligible levels of IgG1, IgG3 e IgG4 antibodies and high levels of IgG2 antibodies against this crude antigen extract. As pointed out by Rodrigues and colleagues in their review [1], the dose of parasites may influence the resulting immune response [32]. Menon & Bretscher [33] also determined that the dose of Leishmania affects the outcome of infection even in genetically susceptible hosts: BALB/c mice can control infection with L. major, a visceralizing parasite in this host, if they receive a low dose of parasites. Dominguez and colleagues [34] and Moreno and colleagues [35] showed that natural antibodies present in normal human sera rapidly (i.e. in 2.5 min) cause lysis of 85–95 % of infective metacyclic Leishmania promastigotes by means of the classical pathway of complement. Thus, Leishmania-reactive antibodies presenting an adequate profile may result in manageable doses of parasites at crucial initial stages of infection with Leishmania by promoting lysis of infective promastigotes inoculated by vectors. This mechanism does not exclude a further role for antibodies with adequate profiles in activating microbicidal mechanisms and expansion of efficacious effector responses through appropriate signaling pathways in Leishmania-infected phagocytic and antigen-presenting cells. Finally, we wish to point out that not only variability at the level of protein within IgG subclasses and the different FcR affects effector mechanisms of antibody-mediated immunity: interactions of IgGs with type I FcR (the canonical FcγRI, FcγRIIa, FcγRIIb, FcγRIIc, FcγRIIIa, FcγRIIIb) or type II FcR (DC-SIGN and CD23) [36]; or with mannan-binding lectin [37] and the complement component C1q [38] are also regulated by the patterns of N-linked, biantennary glycan structures attached to Asn 297 of the IgG heavy chain [39]. In a recent study, we and our colleagues applied a robust method of IgG Fc N-glycopeptide profiling that demonstrated profound alterations in the patterns of IgG Fc N-glycosylation of VL patients compared with those of asymptomatic individuals and non-infected controls [40]. In fact, the profile of IgG Fc glycans presented by the VL patients that we examined is compatible with and may contribute to the imbalance of the inflammatory milieu that Rodrigues and colleagues suggest is unfavorable for proper differentiation of T follicular helper cells [1]. In our opinion, those alterations are extremely relevant and should be considered in future studies addressing immunopathological or protective responses in infections with Leishmania, which might depend on the clinical context after infection and possibly affect bystander inflammatory processes [41], B cell activation and regulation [42] and antibody-mediated effector functions.

Abbreviations

FcγR, Fc-gamma receptor; VL, visceral leishmaniasis
  42 in total

1.  Specific cleavage sites on human IgG subclasses by cruzipain, the major cysteine proteinase from Trypanosoma cruzi.

Authors:  Patricia Berasain; Carlos Carmona; Blas Frangione; Juan José Cazzulo; Fernando Goñi
Journal:  Mol Biochem Parasitol       Date:  2003-08-11       Impact factor: 1.759

2.  μ-chain-deficient mice possess B-1 cells and produce IgG and IgE, but not IgA, following systemic sensitization and inhalational challenge in a fungal asthma model.

Authors:  Sumit Ghosh; Scott A Hoselton; Jane M Schuh
Journal:  J Immunol       Date:  2012-06-25       Impact factor: 5.422

3.  IgG1 is pathogenic in Leishmania mexicana infection.

Authors:  Niansheng Chu; Bolaji N Thomas; Supriya R Patel; Laurence U Buxbaum
Journal:  J Immunol       Date:  2010-10-29       Impact factor: 5.422

4.  Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation.

Authors:  Eszter Deak; Asha Jayakumar; Ka Wing Cho; Karen Goldsmith-Pestana; Blaise Dondji; John D Lambris; Diane McMahon-Pratt
Journal:  Eur J Immunol       Date:  2010-05       Impact factor: 5.532

5.  Cloning and characterization of a gene encoding an immunoglobulin-binding receptor on the cell surface of some members of the family Trypanosomatidae.

Authors:  Antonio Campos-Neto; Isabelle Suffia; Karen A Cavassani; Shyian Jen; Kay Greeson; Pamela Ovendale; João S Silva; Steven G Reed; Yasir A W Skeiky
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

6.  IgG subclass profile of serum antibodies to Leishmania chagasi in naturally infected and vaccinated dogs.

Authors:  Trícia M F S Oliveira; Tiago W P Mineo; Melina Bason; Michael J Day; Rosangela Z Machado
Journal:  Vet Parasitol       Date:  2009-02-26       Impact factor: 2.738

7.  Synergistic protection by specific antibodies and interferon against infection by Trypanosoma cruzi in vitro.

Authors:  F Plata; J Wietzerbin; F G Pons; E Falcoff; H Eisen
Journal:  Eur J Immunol       Date:  1984-10       Impact factor: 5.532

8.  Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity.

Authors:  Florian Woelbing; Susanna Lopez Kostka; Katharina Moelle; Yasmine Belkaid; Cord Sunderkoetter; Sjef Verbeek; Ari Waisman; Axel P Nigg; Juergen Knop; Mark C Udey; Esther von Stebut
Journal:  J Exp Med       Date:  2006-01-17       Impact factor: 14.307

9.  Receptor for immunoglobulin Fc on pathogenic but not on nonpathogenic protozoa of the Trypanosomatidae.

Authors:  I K De Miranda-Santos; A Campos-Neto
Journal:  J Exp Med       Date:  1981-12-01       Impact factor: 14.307

Review 10.  Regulation of immunity during visceral Leishmania infection.

Authors:  Vasco Rodrigues; Anabela Cordeiro-da-Silva; Mireille Laforge; Ricardo Silvestre; Jérôme Estaquier
Journal:  Parasit Vectors       Date:  2016-03-01       Impact factor: 3.876

View more
  2 in total

1.  Identification of Immunodominant Antigens From a First-Generation Vaccine Against Cutaneous Leishmaniasis.

Authors:  María José Germanó; Juan Pablo Mackern-Oberti; Jessica Gardone Vitório; Mariana Costa Duarte; Daniel Carvalho Pimenta; Maria Victoria Sanchez; Flavia Alejandra Bruna; Esteban Sebastián Lozano; Ana Paula Fernandes; Diego Esteban Cargnelutti
Journal:  Front Immunol       Date:  2022-05-12       Impact factor: 8.786

2.  Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis.

Authors:  Pedro Cecílio; Begoña Pérez-Cabezas; Laura Fernández; Javier Moreno; Eugenia Carrillo; José M Requena; Epifanio Fichera; Steven G Reed; Rhea N Coler; Shaden Kamhawi; Fabiano Oliveira; Jesus G Valenzuela; Luigi Gradoni; Reinhard Glueck; Gaurav Gupta; Anabela Cordeiro-da-Silva
Journal:  PLoS Negl Trop Dis       Date:  2017-11-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.